Jacek Jassem

57.3k citations
523 papers · 19.9k · 6 hit papers · h-index 59

Impact in

    • Head and Neck Cancer Studies
  • Oncology top 0.05%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Cancer Treatment and Pharmacology
    • Cancer Immunotherapy and Biomarkers

Papers in

    • Lung Cancer Research Studies 75
    • Cancer Treatment and Pharmacology 71
    • HER2/EGFR in Cancer Research 60
    • Colorectal Cancer Treatments and Studies 35
    • Lung Cancer Treatments and Mutations 124
    • Lung Cancer Diagnosis and Treatment 55

Jacek Jassem

497 papers receiving 19.4k citations

Jacek Jassem's Hit Papers

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study 2022 · 129 citations
1290+7+14Years since publication10002.0k3.0k

Peers

Jacek Jassem
Comparison fields: 5 of 160
  • Otorhinolaryngology 3.3k
  • Oncology 11.4k
  • Cancer Research 3.9k
  • Pulmonary and Respiratory Medicine 8.0k
  • Hepatology 719
Replace Eric K. Rowinsky with:
Eric K. Rowinsky United States
Danny Rischin Australia
Ahmad Awada Belgium
George Fountzilas Greece
Benjamin Solomon Australia
Brigette Ma Hong Kong
Lisa Licitra Italy
David R. Gandara United States
Enriqueta Felip Spain
Marianna Zahurak United States
Jacek Jassem relative to Eric K. Rowinsky United States Eric K. Rowinsky's profile →
Citations per field
00.5×1.5×1.9×
Eric K. Rowinsky · 1×
Citations per year

Countries citing papers authored by Jacek Jassem

Since Specialization
Citations

This map shows the geographic impact of Jacek Jassem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacek Jassem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacek Jassem more than expected).

Fields of papers citing papers by Jacek Jassem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacek Jassem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacek Jassem. The network helps show where Jacek Jassem may publish in the future.

Co-authors

The 25 scholars most cited alongside Jacek Jassem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jacek Jassem Line = papers co-authored together Jacek Jassem links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 523 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Hit paper breakdown →
20063707
2
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Hit paper breakdown →
20101351
3
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
Hit paper breakdown →
20051175
4
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Hit paper breakdown →
2015688
5 2009483
6 2007383
7
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
Hit paper breakdown →
2018281
8 2008268
9 2006256
10 2013245
11 2017239
12 2001230
13 1989193
14 2004188
15 2007186
16 2008178
17 2007167
18 2010167
19 2008164
20 2011161

About Jacek Jassem

Jacek Jassem is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Surgery, having authored 523 papers that have together received 19.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (124 papers), Lung Cancer Research Studies (75 papers), Cancer Treatment and Pharmacology (71 papers), Breast Cancer Treatment Studies (60 papers), HER2/EGFR in Cancer Research (60 papers), Lung Cancer Diagnosis and Treatment (55 papers), Cancer Genomics and Diagnostics (42 papers) and Colorectal Cancer Treatments and Studies (35 papers). The work is most often cited by research in Otorhinolaryngology (3.3k citations), Oncology (11.4k citations), Cancer Research (3.9k citations), Pulmonary and Respiratory Medicine (8.0k citations) and Hepatology (719 citations). Jacek Jassem has collaborated with scholars based in Poland, United States and Italy. Frequent co-authors include James A. Bonner, Paul M. Harari, José Baselga, J. Giralt, Nadia Amellal, Eric K. Rowinsky, Roger B. Cohen, Merrill S. Kies, Dong M. Shin and N. Azarnia. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, European Journal of Cancer, Annals of Oncology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact